openPR Logo
Press release

62,000 estimated cases of Leukemia in 2019 in the U.S.- American Cancer Society

06-07-2019 12:42 PM CET | Health & Medicine

Press release from: DataM Intelligence 4Market Research

62,000 estimated cases of Leukemia in 2019 in the U.S.- American

The market report titled ‘Global Leukemia Market – Size, Share and Forecast (2019-2026)’ by DataM Intelligence analyses the industry dynamics in this competitive space to provide a comprehensive analysis of the market opportunities.

Leukemia occurs most often in adults older over the age of 55. Among cancers, the incidence rate of Leukemia is highest among children younger than 15. According to ACS, around 3 out of 4, childhood leukemias are Acute Lymphocytic Leukemia.
Leukemia Market- Segmentation

The global leukemia market can be segmented by

Disease type as Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Chronic Myeloid Leukemia.
Over the period of forecast(2019-2016) incidence of Acute Lymphocytic Leukemia is expected to grow, leading to growth in their therapeutics market.

Treatment type as Medication, Surgery, Chemotherapy, Biological Therapy, Immunotherapy, Radiation Therapy, Targeted Therapy, and Stem Cell Transplantation.
Chemotherapy is the dominant treatment for most people with leukemia.

Leukemia Market- Regional Distribution

North America is expected to dominate the market in the forecast period followed by Europe. This is due to healthcare access, favorable reimbursement policies, advanced healthcare infrastructure and high disease prevalence.

Asia Pacific is anticipated to have the highest growth rate in the forecast period due to the development of healthcare infrastructure in China and India. Plus, investment in R&D activities is projected to accelerate the growth of the leukemia market in the region.
In the southern hemisphere, the World Health Organization (WHO) data indicates that Australia and New Zealand have the highest regional leukemia rate in the world- about 11.3 per 100,000 population.

Visit the link below to get a free sample market report-
https://www.datamintelligence.com/research-report/leukemia-market/

Listed below are the topics covered in this market research report-
1. Global Leukemia Market Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Global Leukemia Market – Market Definition and Overview
3. Global Leukemia Market – Executive Summary
3.1. Market Snippet by Disease Type
3.2. Market Snippet by Treatment Type
3.3. Market Snippet by Region
3.4. DataM CLO Scenario
4. Global Leukemia Market – Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in prevalence population
4.1.1.2. Drug launches and robust pipeline
4.1.1.3. Rise in healthcare expenditure
4.1.2. Restraints
4.1.2.1. High costs associated with drug development
4.1.2.2. Adverse side-effects
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Global Leukemia Market – Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Regulatory Analysis
5.3. Epidemiology
5.4. Pipeline Insights
5.5. Key Companies to Watch
6. Global Leukemia Market – By Disease Type
6.1. Introduction
6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
6.3. Market Attractiveness Index, By Disease Type
6.4. Acute Lymphocytic Leukemia
6.4.1. Introduction
6.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
6.5. Chronic Lymphocytic Leukemia
6.6. Acute Myeloid Leukemia
6.7. Chronic Myeloid Leukemia
7. Global Leukemia Market – By Treatment Type
7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
7.3. Market Attractiveness Index, By Treatment Type
7.4. Surgery
7.4.1. Introduction
7.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
7.5. Chemotherapy
7.6. Immunotherapy
7.7. Radiation Therapy
7.8. Targeted Therapy
7.9. Stem Cell Transplantation
8. Global Leukemia Market – By Region
8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
8.3. Market Attractiveness Index, By Region
8.4. North America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. U.S.
8.4.5.2. Canada
8.4.5.3. Mexico
8.5. Europe
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. Germany
8.5.5.2. U.K.
8.5.5.3. France
8.5.5.4. Italy
8.5.5.5. Spain
8.5.5.6. Rest of Europe
8.6. South America
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
8.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.6.5.1. Brazil
8.6.5.2. Argentina
8.6.5.3. Rest of South America
8.7. Asia-Pacific
8.7.1. Introduction
8.7.2. Key Region-Specific Dynamics
8.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
8.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
8.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
8.7.5.1. China
8.7.5.2. India
8.7.5.3. Japan
8.7.5.4. Australia
8.7.5.5. Rest of Asia Pacific
8.8. Middle East and Africa
8.8.1. Introduction
8.8.2. Key Region-Specific Dynamics
8.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
8.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
9. Global Market – Competitive Landscape
9.1. Competitive Scenario
9.2. Competitor Leukemia Strategy Analysis
9.3. Comparative Product Portfolio Analysis
9.4. Market Positioning/Share Analysis
9.5. Mergers and Acquisitions Analysis
10. Company Profiles
10.1. AbbVie, Inc. *
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Key Highlights
10.1.4. Financial Overview
10.2. Novartis
10.3. Pfizer
10.4. Bristol-Myers Squibb Company
10.5. Genzyme
10.6. Celgene
10.7. GlaxoSmithKline
10.8. Cephalon
10.9. Eisai
10.10. Teva Pharmaceuticals
10.11. Company XX
10.12. Company XX
11. Global Leukemia Market – Premium Insights
12. Global Leukemia Market – DataM
12.1. Appendix
12.2. About Us and Services
12.3. Contact Us

1st floor, Phoenix Tech Tower, Plot no: 14/46, Habsidguda, IDA-Uppal, Hyderabad-500039, Telangana

About DataM Intelligence

DataM Intelligence 4Market Research is a Market Intelligence and Business Research firm, based in India. It aims to bridge the two main aspects of a business decision - opinion and supportive data.

DMI is currently strengthening its cross-industrial database for sectors including Chemicals, Materials, Agriculture, Healthcare Services, Animal Nutrition, Consumer Goods, Food & Beverages, Industrial Machinery, and Automation among others.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release 62,000 estimated cases of Leukemia in 2019 in the U.S.- American Cancer Society here

News-ID: 1767905 • Views:

More Releases from DataM Intelligence 4Market Research

Automotive Testing Market Size, Share, Industry, Forecast and Outlook (2024-2031)
Automotive Testing Market Size, Share, Industry, Forecast and Outlook (2024-2031 …
Market Overview Global Automotive Testing Market reached USD million in 2022 and is projected to witness lucrative growth by reaching up to USD million by 2030. The market is growing at a CAGR of 4.2% during the forecast period (2023-2030). The automotive testing industry encompasses a range of assessments involving complete vehicles, components, and systems. These evaluations occur across various settings, including laboratories, virtual simulations, and real-world scenarios. The primary objective of
Ankle Replacement Devices Market Size, Share, Industry, Forecast and outlook (2024-2031)
Ankle Replacement Devices Market Size, Share, Industry, Forecast and outlook (20 …
Global Ankle Replacement Devices Market to Witness Substantial Growth by 2031, Forecasts Research The global ankle replacement devices market, which reached a value of US$ million in 2023, is projected to exhibit significant expansion, reaching US$ million by 2031, according to a recent market analysis conducted by [Research Company]. The market is anticipated to grow at a notable CAGR during the forecast period spanning from 2024 to 2031. Ankle replacement devices, also
Carbon Dioxide Monitor Market Size, Share, Industry, Forecast and outlook (2024-2031)
Carbon Dioxide Monitor Market Size, Share, Industry, Forecast and outlook (2024- …
Global Carbon Dioxide Monitor Market Projected to Reach $ Million by 2031, Indicating a Steady Growth Trajectory The worldwide carbon dioxide monitor market witnessed significant growth in 2023, reaching a valuation of US$ million. Forecasts indicate a promising upward trend, with expectations to hit US$ million by 2031, boasting a Compound Annual Growth Rate (CAGR) of during the forecast period spanning 2024 to 2031. Carbon dioxide monitors, also known as CO2 detectors
United States Prosthetic Contact Lenses Market Size, Share, Growth, Forecast and Outlook (2024-2031)
United States Prosthetic Contact Lenses Market Size, Share, Growth, Forecast and …
United States Prosthetic Contact Lenses Market Projected to Expand Significantly by 2031 The United States Prosthetic Contact Lenses Market, which achieved a valuation of US$ billion in 2023, is anticipated to witness substantial growth, reaching US$ million by 2031. This growth trajectory reflects a robust Compound Annual Growth Rate (CAGR) during the forecast period from 2024 to 2031. Prosthetic contact lenses are meticulously designed to enhance the aesthetic appearance of the eye

All 5 Releases


More Releases for Leukemia

Pipeline Review, H2 2017 of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic …
"Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- '
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, T …
Orbisreserach.Com Adds “H1 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Market Pipeline Review 2017 Trend Analysis Report Report” To Its Research Database Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape. Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the
Acute Lymphoblastic Leukemia (ALL) Market grows with high incidence of acute lym …
Acute lymphoblastic leukemia (ALL) is a cancer of white blood cells called as lymphocytes in bone marrow. It is a malignant disease in which early precursor lymphoid cells proliferate and replace the normal hematopoietic cells of bone marrow. ALL is the most common type of cancer in children. There is overproduction of lymphoblasts in the bone marrow when a person suffers from ALL that continuously multiply, damaging the bone marrow
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Tri …
ReportsWorldwide has announced the addition of a new report title Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth